Assessment of Mealtime Bolus Insulin Behavior

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

79 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-12-11

Study Completion Date

2018-07-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study is to estimate missed bolus insulin doses in diabetics. This is a 12-week, single-arm, outpatient, exploratory study with two study periods in Type 1 or Type 2 diabetics, with an investigational reusable injection pen, insulin, and a Continuous Glucose Monitoring (CGM) device.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prolongation of GLP-1 Adherence When Using Continuous Glucose Monitoring

NCT06668935

Diabetes Mellitus

RECRUITING

A Study of Glucose Control in Participants With Type 1 and Type 2 Diabetes

NCT04667182

Type 1 Diabetes Type 2 Diabetes

WITHDRAWN

A Study of Technology to Improve Glucose Control in Participants With Type 1 Diabetes

NCT03758430

Diabetes Mellitus, Type 1

COMPLETED

The Steno Opti-Bolus-Timing Studies

NCT07021690

Type 1 Diabetes (T1D)

NOT_YET_RECRUITING NA

Connected Pens for Diabetes Study

NCT03830216

Diabetes Mellitus

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Blinded CGM (Continuous Glucose Monitoring)

Participants received Insulin lispro 100 U/mL (units per millilitre) injected via the pen and they were blinded to CGM device recording as directed in study period 1.

Continuous Glucose Monitoring

Intervention Type DEVICE

Commercially available

Insulin Lispro

Intervention Type DRUG

As prescribed.

Unblinded CGM

Participants received Insulin lispro 100 U/mL injected via the pen and they were unblinded to CGM device recording as directed in study period 2.

Continuous Glucose Monitoring

Intervention Type DEVICE

Commercially available

Insulin Lispro

Intervention Type DRUG

As prescribed.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Continuous Glucose Monitoring

Commercially available

Intervention Type DEVICE

Insulin Lispro

As prescribed.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have a Type 1 Diabetes Mellitus (T1D) or a Type 2 Diabetes Mellitus (T2D) diagnosis
* Must be taking a mealtime bolus dose insulin, greater than or equal to (≥) 3 doses
* Each individual bolus insulin dose must be less than (\<) 40 units
* Must be taking a stable insulin dose regimen for the last 3 months
* Must be taking a bolus insulin analog (for example insulin lispro \[U-100\]/\[U-200\], insulin aspart, or insulin glulisine). In addition, must be able to switch to insulin lispro U-100 for the duration of the trial
* Must have a hemoglobin A1c (HbA1c) ≥8.0% in the last 6 months
* Participants with T1D must be ≥21 to less than or equal to (≤) 65 years of age. Participants with T2D must be ≥35 to ≤65 years of age
* Women of childbearing potential must meet the following: (Note: females of childbearing potential are defined as those who have experienced menarche and who are NOT permanently sterile or postmenopausal. Postmenopausal is defined as 12 consecutive months with no menses without an alternative medical cause)

* Must agree to use 1 highly effective method of contraception, or a combination of 2 effective methods of contraception for the entirety of the study
* Must test negative for pregnancy as indicated by a negative serum or urine pregnancy test
* Participants with prior CGM/flash glucose monitoring experience must have stopped CGM/flash glucose monitoring ≥3 months prior to enrollment

Exclusion Criteria

* Have known tape/adhesive allergies with CGM sensors
* Medical conditions, visual, physical, psychiatric, or cognitive impairment(s) that may preclude the ability to participate in the trial
* Have history of liver disease, acute or chronic hepatitis, or alanine aminotransferase or aspartate aminotransferase levels ≥3 times the upper limit of the reference range within the last 6 months
* Have history of chronic kidney disease stage 4 and higher within the last 6 months, or history of renal transplantation
* Have active malignancy
* Are pregnant or planning to become pregnant
* Are on or are intending to begin a weight loss program
* Participants with T1D who have taken off-label antihyperglycemic agents within last 3 months
* Have received insulin by continuous subcutaneous insulin infusion in the last 3 months
* Participants taking opioid medications for medically invalid reasons or at doses considered excessive
* Participants on routine use of acetaminophen
* Currently undergoing systemic treatment with:

* Immunosuppressive medication
* Chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy (excluding topical and inhaled preparations) or have received such therapy within the prior 2 weeks
* Are currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study
* Have participated, within the last 30 days, in a clinical study involving an investigational product
* Are unwilling or unable to comply with the use of a data collection device to directly record data

Minimum Eligible Age

21 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No